AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |
Back to Blog
Nvax stock conversations9/24/2023 ![]() We’re far from the end of the pandemic, and Novavax could provide the incremental vaccine doses the world needs. Weekly Stock List Value stocks - a market segment that includes high-yield stocks - outperformed growth stocks in 2022 for the first time since. That said, outside of the U.S., tremendous opportunity lies for Novavax to grab market share and deliver vaccines. is the key catalyst that’s driving investor interest in this stock. However, this article highlights a number of other headwinds many seem to think are unwarranted.Ĭurrently, Novavax’s approval process in the U.S. Some supporters did note concern with Novavax’s self-imposed deadline of an FDA filing before the end of the year. Out of 22 panelists, 21 said the benefits of the Novavax shot outweigh its. Unsurprisingly, these concerns were met with a certain amount of vitriol by Novavax supporters on social media. NVAX Stock: FDA Decision Next The meeting is an important step ahead of potential authorization of the two-dose vaccine. A POLITICO article released this morning highlighted concerns not only with respect to Novavax’s ability to get its drug approved by the FDA, but also concerns around the production capacity for this vaccine maker. by the end of January 2022.īesides the delay on the FDA filing, there’s another catalyst driving NVAX stock today. In terms of timeline, that means Novavax now intends to file for emergency-use authorization in the U.S. ![]() Instead, the company announced today that it has filed its last data packages with U.S. Many were hopeful that by the end of the year, the company would file with the FDA for emergency-use authorization. ![]() Leading into today, investors have been getting antsy with Novavax. What’s Behind Today’s Decline in NVAX Stock ![]()
0 Comments
Read More
Leave a Reply. |